- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about edit
Recent news which mentions edit
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
From Benzinga
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
November 17, 2022
From Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
November 17, 2022
From Benzinga
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
November 17, 2022
Tickers
EDIT
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 17, 2022
From Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
November 17, 2022
From Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
November 17, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 17, 2022
From Benzinga
What 5 Analyst Ratings Have To Say About Editas Medicine
November 03, 2022
Tickers
EDIT
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
From Benzinga
From Benzinga
Down 35% This Year, Is This Small-Cap Stock a Buy?
July 21, 2022
From Motley Fool
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
From InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
From InvestorPlace
From Motley Fool
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
From Benzinga
From Benzinga
From InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
June 07, 2022
From Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
June 02, 2022
From InvestorPlace
Why Editas Medicine's Shares Fell 28.9% This Week
May 13, 2022
From Motley Fool
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.